Trial Profile
A Study of Durvalumab (MEDI4736), as an Adjuvant Therapy, Compared to Observation Alone, in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma (BR PDA) Following Neoadjuvant Therapy and Successful Surgical Resection
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2020
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 10 Sep 2020 Planned initiation date changed from 25 Dec 2017 to 12 Jun 2017.
- 10 Sep 2020 Planned End Date changed from 1 Dec 2019 to 1 Apr 2019.
- 10 Sep 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Apr 2019.